{
  "ticker": "SRRK",
  "company_name": "Scholar Rock Holding Corporatio",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04291079",
      "title": "SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Cancer",
      "start_date": "2020-04-23",
      "completion_date": "2025-04-14",
      "enrollment": 0,
      "sponsor": "Scholar Rock, Inc."
    },
    {
      "nct_id": "NCT06877689",
      "title": "EAP of Apitegromab for Patients With Spinal Muscular Atrophy",
      "status": "AVAILABLE",
      "phase": "",
      "condition": "SMA",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Scholar Rock, Inc."
    },
    {
      "nct_id": "NCT07047144",
      "title": "A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations, Anti-myostatin",
      "start_date": "2025-09-15",
      "completion_date": "2029-03",
      "enrollment": 0,
      "sponsor": "Scholar Rock, Inc."
    },
    {
      "nct_id": "NCT06445075",
      "title": "Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Overweight and Obesity",
      "start_date": "2024-05-21",
      "completion_date": "2025-06-17",
      "enrollment": 0,
      "sponsor": "Scholar Rock, Inc."
    },
    {
      "nct_id": "NCT06419322",
      "title": "Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy (SMA).",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "NA",
      "condition": "Spinal Muscular Atrophy",
      "start_date": "2024-06-01",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "University of Oxford"
    },
    {
      "nct_id": "NCT03921528",
      "title": "An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations",
      "start_date": "2019-04-22",
      "completion_date": "2024-02-28",
      "enrollment": 0,
      "sponsor": "Scholar Rock, Inc."
    },
    {
      "nct_id": "NCT05156320",
      "title": "Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin",
      "start_date": "2022-04-14",
      "completion_date": "2024-12-18",
      "enrollment": 0,
      "sponsor": "Scholar Rock, Inc."
    },
    {
      "nct_id": "NCT05626855",
      "title": "Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin",
      "start_date": "2023-04-17",
      "completion_date": "2029-05-02",
      "enrollment": 0,
      "sponsor": "Scholar Rock, Inc."
    }
  ],
  "summary": {
    "total_trials": 8,
    "by_phase": {
      "PHASE1": 1,
      "": 1,
      "PHASE2": 3,
      "NA": 1,
      "PHASE3": 2
    },
    "by_status": {
      "COMPLETED": 4,
      "AVAILABLE": 1,
      "RECRUITING": 1,
      "ACTIVE_NOT_RECRUITING": 2
    },
    "active_trials": 3,
    "completed_trials": 4,
    "conditions": [
      "Cancer",
      "Overweight and Obesity",
      "SMA",
      "Spinal Muscular Atrophy",
      "Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations, Anti-myostatin",
      "Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations",
      "Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:22:05.017243",
    "search_query": "Scholar Rock Holding Corporatio",
    "url": "https://clinicaltrials.gov/search?term=Scholar+Rock+Holding+Corporatio"
  }
}